-- MediSwitch Drug Interactions Import (Part 51/112)
INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(30764, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(30764, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(30764, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(30764, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(20886, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(20886, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(20886, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(20886, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(3900, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(3900, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(3900, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(3900, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(28539, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(28539, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(6828, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(6828, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(6828, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(6828, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(29463, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(29463, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(29463, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(29463, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(1951, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(1951, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(1951, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(1951, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(15731, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(15731, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(15731, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(15731, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(33113, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(33113, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(33113, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(33113, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(28919, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(28919, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(13731, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(13731, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(2269, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(2269, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(21474, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(21474, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(4917, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(4917, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(4917, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(4917, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(32374, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(32374, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(32374, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(32374, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(26671, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(26671, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26671, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(26671, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(16105, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(16105, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(31333, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(31333, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(15481, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(15481, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(15481, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(15481, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(17331, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(17331, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(17331, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(17331, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(10219, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(10219, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(10219, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(10219, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(5984, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(5984, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(5984, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(5984, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(8973, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(8973, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(18846, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(18846, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(18846, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(18846, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(9601, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(9601, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(9601, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(9601, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(31978, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(31978, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(31978, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(31978, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(28888, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(28888, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(7898, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(7898, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(7898, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(7898, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(24399, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(24399, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(13812, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(13812, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(13812, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(13812, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(20817, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(20817, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(2317, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(2317, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(2317, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(2317, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(32303, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(32303, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(32303, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(32303, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(33057, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(33057, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(2982, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(2982, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(2982, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(2982, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(12425, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(12425, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(21963, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(21963, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(21963, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(21963, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(19105, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(19105, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(19105, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(19105, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(12493, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(12493, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(12493, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(12493, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(15609, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(15609, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(15609, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(15609, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(31662, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(31662, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(31682, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(31682, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(31682, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(31682, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(25208, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(25208, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(11032, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(11032, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(11032, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(11032, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(30766, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(30766, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(30766, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(30766, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(31883, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(31883, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(30306, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(30306, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(30306, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(30306, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(8222, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(8222, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(26448, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(26448, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26448, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(26448, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(7809, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(7809, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(7809, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(7809, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(15197, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(15197, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(15197, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(15197, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(33325, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(33325, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(33325, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(33325, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(22434, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(22434, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(22434, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(22434, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(14647, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(14647, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(14647, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(14647, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(22865, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(22865, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(22865, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(22865, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(26819, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(26819, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26819, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(26819, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(20239, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(20239, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(20239, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(20239, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(9148, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(9148, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(22308, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(22308, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(22308, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(22308, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(31833, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(31833, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(5200, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(5200, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(5200, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(5200, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(15608, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(15608, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(15608, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(15608, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(29044, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(29044, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(3670, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(3670, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(3670, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(3670, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(29943, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(29943, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(29943, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(29943, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(33605, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(33605, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(33605, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(33605, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(15011, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(15011, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(15011, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(15011, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(11119, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(11119, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(11119, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(11119, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(31871, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(31871, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(17716, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(17716, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(17716, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(17716, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(28882, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(28882, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(28882, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(28882, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(21170, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(21170, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(21170, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(21170, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(26332, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(26332, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26332, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(26332, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(31718, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(31718, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(31718, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(31718, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(30252, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(30252, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(30252, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(30252, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(27439, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(27439, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(26449, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(26449, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26449, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(26449, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(21488, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(21488, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(21488, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(21488, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(32196, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(32196, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(32196, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(32196, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(33389, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(33389, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(33389, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(33389, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(22323, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(22323, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(22323, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(22323, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(3491, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(3491, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(13299, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(13299, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(13299, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(13299, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(28248, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(28248, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(28248, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(28248, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(3447, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(3447, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(3447, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(3447, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(33285, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(33285, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(33285, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(33285, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(30984, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(30984, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(33753, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(33753, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(33753, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(33753, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(7695, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(7695, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(13415, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(13415, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(13415, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(13415, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(2840, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(2840, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(2090, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(2090, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(2090, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(2090, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(22070, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(22070, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(22070, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(22070, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(23515, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(23515, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(23515, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(23515, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(15907, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(15907, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(15907, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(15907, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(29356, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(29356, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(29356, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(29356, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(26748, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26748, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(32126, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(32126, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(32126, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(32126, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(6004, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(6004, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(6004, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(6004, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(32810, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(32810, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(25753, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(25753, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(25753, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(25753, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(1686, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(1686, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(1686, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(1686, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(32852, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(32852, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(32852, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(32852, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(22379, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(22379, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(15468, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(15468, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(15468, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(15468, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(22488, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(22488, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(22488, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(22488, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(30077, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(30077, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(30077, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(30077, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(19761, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(19761, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(19761, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(19761, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(33594, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(33594, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(33594, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(33594, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(362, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(362, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(362, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(362, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(15418, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(15418, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(15418, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(15418, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(29506, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(29506, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(29506, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(29506, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(32210, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(32210, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(32210, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(32210, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(773, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(773, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(773, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(773, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(26509, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26509, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(26792, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(26792, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26792, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(26792, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(8223, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(8223, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(11309, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(11309, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(8044, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(8044, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(8044, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(8044, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(25840, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(25840, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(25840, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(25840, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(16820, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(16820, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(16820, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(16820, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(27290, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(27290, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(27290, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(27290, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(4954, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(4954, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(12429, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(12429, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(16887, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(16887, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(16887, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(16887, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(32320, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(32320, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(20188, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(20188, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(20188, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(20188, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(32202, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(32202, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(32202, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(32202, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(16195, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(16195, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(16195, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(16195, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(30585, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(30585, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(7018, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(7018, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(7018, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(7018, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(25263, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(25263, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(25263, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(25263, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(20974, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(20974, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(20974, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(33533, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(33533, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(2954, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(2954, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(2954, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(2954, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(32000, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(32000, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(32000, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(32000, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(15398, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(15398, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(15398, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(15398, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(9084, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(9084, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(9084, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(9084, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(1049, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(1049, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(6770, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(6770, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(6770, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(6770, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(27253, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(27253, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(27253, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(27253, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(28115, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(28115, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(28115, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(28115, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(33361, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(33361, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(18971, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(18971, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(18971, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(18971, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(25380, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(25380, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(25380, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(25380, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(10299, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(10299, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(14752, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(14752, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(14752, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(14752, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(28923, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(28923, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(28923, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(28923, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(9256, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(9256, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(9256, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(9256, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(25825, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(25825, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(25825, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(25825, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(6781, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(6781, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(6781, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(6781, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(18963, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(18963, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(13295, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(13295, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(13295, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(13295, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(25798, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(25798, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(25798, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(25798, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(11269, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(11269, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(11269, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(11269, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(5907, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(5907, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(29292, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(29292, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(29292, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(29292, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(31587, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(31587, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(16888, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(16888, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(16888, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(16888, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(4000, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(4000, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(4000, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(4000, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(6345, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(6345, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(6345, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(6345, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(13040, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(13040, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(20965, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(20965, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(17856, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(17856, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(17856, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(17856, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(17734, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(17734, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(17734, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(17734, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(7396, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(7396, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(7396, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(7396, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(4219, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(4219, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(4219, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(4219, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(2371, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(2371, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(19884, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(19884, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(19884, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(19884, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(20240, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(20240, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(20240, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(20240, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(23350, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(23350, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(23350, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(23350, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(23329, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(23329, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(10124, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(10124, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(6866, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(6866, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(6866, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(6866, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(31722, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(31722, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(31722, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(31722, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(27233, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(27233, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(27233, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(27233, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(24816, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(24816, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(24816, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(24816, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(28250, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(28250, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(28250, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(28250, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(26732, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(26732, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26732, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(26732, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(20612, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(20612, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(13377, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(13377, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(13377, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(13377, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(6559, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(6559, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(3110, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(3110, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(20409, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(20409, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(20409, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(20409, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(25976, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(25976, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(25976, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(25976, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(23212, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(23212, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(6827, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(6827, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(6827, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(6827, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(21690, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(21690, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(33359, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(33359, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(30561, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(30561, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(30561, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(30561, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(25056, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(25056, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(21577, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(21577, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(3143, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(3143, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(3143, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(3143, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(17671, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(17671, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(17671, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(17671, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(7343, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(7343, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(26388, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(26388, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26388, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(26388, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(14295, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(14295, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(14295, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(14295, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(1770, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(1770, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(1770, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(1770, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(3539, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(3539, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(22106, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(22106, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(22106, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(22106, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(6789, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(6789, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(6789, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(6789, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(13856, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(13856, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(13856, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(13856, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(22132, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(22132, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(22132, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(22132, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(20342, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(20342, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(4303, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(4303, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(4303, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(4303, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(25379, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(25379, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(25379, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(25379, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(15922, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(15922, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(6342, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(6342, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(26813, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(26813, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26813, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(26813, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(16017, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(16017, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(16017, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(16017, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(18674, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(18674, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(18674, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(18674, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(33564, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(33564, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(33564, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(33564, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(2092, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(2092, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(2092, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(2092, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(23217, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(23217, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(23217, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(23217, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(31541, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(31541, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(16302, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(16302, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(16302, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(16302, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(13206, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(13206, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(13206, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(13206, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(4976, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(4976, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(4976, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(4976, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(11320, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(11320, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(11320, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(11320, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(16747, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(16747, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(16747, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(16747, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(30909, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(30909, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(30909, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(30909, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(31306, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(31306, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(31306, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(31306, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(32109, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(32109, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(3227, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(3227, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(2304, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(2304, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(2304, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(2304, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(16921, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(16921, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(16921, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(16921, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(29086, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(29086, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(29086, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(29086, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(25860, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(25860, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(25860, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(25860, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(25411, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(25411, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(25411, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(25411, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(33544, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(33544, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(32063, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(32063, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(32063, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(32063, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(4572, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(4572, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(32021, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(32021, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(32021, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(32021, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(12574, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(12574, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(12574, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(12574, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(18785, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(18785, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(18785, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(18785, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(31715, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(31715, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(31715, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(31715, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(26818, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(26818, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26818, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(26818, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(30298, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(30298, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(20471, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(20471, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(20471, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(20471, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(5001, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(5001, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(5001, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(5001, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(26510, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26510, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(1521, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(1521, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(30331, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(30331, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(30331, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(30331, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(2728, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(2728, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(2728, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(2728, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(23606, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(23606, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(23606, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(23606, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(22531, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(22531, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(6256, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(6256, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(6256, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(6256, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(23966, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(23966, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(23966, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(33318, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(33318, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(33318, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(33318, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(2360, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(2360, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(2360, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(2360, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(2813, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(2813, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(2813, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(2813, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(23593, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(23593, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(14092, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(14092, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(32095, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(32095, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(22321, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(22321, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(22321, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(22321, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(21970, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(21970, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(21970, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(21970, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(31804, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(31804, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(31804, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(31804, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(28661, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(28661, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(31797, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(31797, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(31797, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(31797, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(3234, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(3234, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(6156, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(6156, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(6156, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(6156, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(6330, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(6330, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(9541, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(9541, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(24361, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(24361, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(28213, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(28213, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(28213, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(28213, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(12522, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(12522, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(12522, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(12522, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(5779, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(5779, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(30896, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(30896, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(7907, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(7907, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(7907, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(7907, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(7446, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(7446, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(7446, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(7446, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(10302, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(10302, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(15684, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(15684, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(15684, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(15684, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(13124, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(13124, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(13124, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(13124, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(6943, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(6943, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(6943, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(6943, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(28700, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(28700, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(28700, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(28700, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(15906, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(15906, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(15874, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(15874, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(15874, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(15874, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(8699, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(8699, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(8699, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(8699, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(7779, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(7779, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(7779, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(7779, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(4269, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(4269, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(4269, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(4269, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(20608, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(20608, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(20608, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(20608, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(19482, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(19482, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(19482, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(19482, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(16509, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(16509, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(25952, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(25952, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(25952, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(25952, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(918, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(918, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(6358, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(6358, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(1343, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(1343, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(1343, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(1343, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(21575, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(21575, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(21575, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(21575, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(6769, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(6769, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(6769, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(6769, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(33508, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(33508, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(28635, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(28635, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(32963, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(32963, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(32963, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(32963, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(26399, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26399, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(26734, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(26734, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26734, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(26734, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(6484, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(6484, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(5309, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(5309, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(5309, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(5309, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(26890, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26890, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(25499, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(25499, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(5652, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(5652, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(5652, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(5652, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(2061, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(2061, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(2061, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(2061, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(15469, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(15469, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(1926, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(1926, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(1926, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(1926, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(32125, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(32125, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(32125, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(32125, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(24777, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(24777, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(24777, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(24777, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(13154, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(13154, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(14881, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(14881, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(32313, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(32313, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(32313, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(32313, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(28045, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(28045, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(109, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(109, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(109, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(109, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(33317, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(33317, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(33317, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(33317, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(2056, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(2056, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(2056, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(27231, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(27231, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(27231, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(27231, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(8533, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(8533, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(1364, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(1364, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(1364, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(1364, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(32510, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(32510, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(26850, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(26850, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26850, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(26850, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(16642, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(16642, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(21933, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(21933, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(21933, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(21933, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(15712, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(15712, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(15712, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(15712, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(3450, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(3450, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(3450, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(3450, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(12427, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(12427, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(19493, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(19493, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(19493, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(19493, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(26770, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26770, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(26725, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(26725, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26725, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(26725, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(6029, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(6029, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(6029, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(6029, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(30880, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(30880, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(30880, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(30880, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(13439, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(13439, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(8254, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(8254, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(8254, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(8254, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(30892, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(30892, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(5923, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(5923, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(5923, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(5923, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(1946, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(1946, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(1946, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(1946, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(28904, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(28904, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(28904, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(28904, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(7623, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(7623, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(7623, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(7623, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(32962, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(32962, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(32962, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(32962, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(27229, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(27229, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(27229, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(27229, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(16920, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(16920, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(16920, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(16920, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(14232, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(14232, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(14232, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(14232, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(18016, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(18016, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(18016, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(18016, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(26899, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26899, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(11519, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(11519, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(11519, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(11519, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(21418, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(21418, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(25688, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(25688, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(25688, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(25688, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(26769, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26769, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(20242, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(20242, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(20242, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(20242, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(13579, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(13579, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(13579, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(13579, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(25278, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(25278, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(25278, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(25278, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(1013, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(1013, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(20815, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(20815, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(7642, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(7642, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(25410, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(25410, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(25410, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(25410, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(16892, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(16892, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(16892, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(16892, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(1952, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(1952, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(1952, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(1952, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(11557, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(11557, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(11557, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(11557, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(13730, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(13730, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(19776, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(19776, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(32905, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(32905, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(27464, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(27464, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(33537, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(33537, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(33537, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(33537, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(29307, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(29307, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(29307, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(29307, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(23106, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(23106, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(15868, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(15868, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(15868, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(15868, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(7209, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(7209, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(3055, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(3055, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(3055, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(3055, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(30152, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(30152, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(30152, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(30152, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(22293, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(22293, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(22293, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(22293, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(6328, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(6328, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(30879, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(30879, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(30879, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(30879, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(26401, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(26401, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26401, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(26401, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(6019, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(6019, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(6019, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(6019, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(29962, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(29962, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(29962, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(29962, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(25754, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(25754, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(25754, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(25754, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(12906, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(12906, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(4987, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(4987, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(26663, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(26663, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26663, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(26663, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(29896, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(29896, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(29896, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(29896, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(33085, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(33085, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(33085, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(33085, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(19047, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(19047, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(19047, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(19047, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(12156, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(12156, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(12156, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(12156, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(20816, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(20816, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(2358, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(2358, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(2358, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(2358, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(14837, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(14837, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(13811, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(13811, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(13811, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(13811, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(28660, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(28660, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(32327, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(32327, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(29658, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(29658, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(2841, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(2841, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(26602, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(26602, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26602, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(26602, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(28176, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(28176, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(28176, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(28176, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(18579, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(18579, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(18579, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(18579, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(3221, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(3221, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(3221, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(3221, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(5983, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(5983, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(5983, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(5983, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(29162, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(29162, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(3030, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(3030, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(3030, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(3030, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(31292, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(31292, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(31292, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(31292, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(24771, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(24771, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(24771, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(24771, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(2926, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(2926, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(6560, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(6560, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(6560, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(6560, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(18737, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(18737, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(18737, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(18737, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(32100, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(32100, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(32100, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(32100, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(23561, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(23561, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(23561, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(23561, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(3449, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(3449, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(3449, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(3449, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(4820, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(4820, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(17698, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(17698, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(17698, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(17698, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(28247, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(28247, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(28247, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(28247, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(24063, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(24063, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(24063, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(24063, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(26302, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(26302, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26302, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(26302, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(3276, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(3276, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(4290, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(4290, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(9149, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(9149, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(33908, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(33908, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(27474, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(27474, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(24346, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(24346, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(24346, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(24346, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(1022, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(1022, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(1022, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(1022, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(29572, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(29572, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(27481, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(27481, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(2874, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(2874, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(2874, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(2874, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(29468, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(29468, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(15024, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(15024, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(9873, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(9873, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(30898, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(30898, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(30898, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(30898, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(29508, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(29508, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(29508, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(29508, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(31691, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(31691, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(31691, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(31691, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(29666, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(29666, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(29666, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(29666, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(32189, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(32189, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(32189, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(32189, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(30470, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(30470, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(30470, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(30470, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(24044, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(24044, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(24044, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(24044, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(92, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(92, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(92, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(92, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(15428, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(15428, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(15428, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(15428, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(21997, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(21997, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(21997, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(21997, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(28166, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(28166, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(32897, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(32897, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(30594, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(30594, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(30594, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(30594, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(14962, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(14962, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(4001, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(4001, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(4001, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(4001, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(6760, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(6760, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(6760, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(6760, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(26345, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(26345, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26345, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(26345, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(20482, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(20482, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(6337, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(6337, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(6157, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(6157, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(30626, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(30626, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(30626, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(30626, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(31954, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(31954, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(31954, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(31954, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(23246, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(23246, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(4477, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(4477, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(17313, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(17313, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(17313, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(17313, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(2754, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(2754, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(6263, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(6263, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(6263, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(6263, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(32228, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(32228, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(32228, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(32228, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(30469, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(30469, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(30469, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(30469, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(27230, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(27230, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(27230, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(27230, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(25948, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(25948, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(6815, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(6815, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(6815, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(4493, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(4493, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(4493, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(4493, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(31773, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(31773, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(6042, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(6042, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(6042, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(6042, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(5904, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(5904, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(5904, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(5904, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(28416, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(28416, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(28416, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(28416, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(30850, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(30850, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(30850, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(30850, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(24103, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(24103, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(24103, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(24103, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(12985, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(12985, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(12985, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(12985, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(29466, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(29466, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(23514, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(23514, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(23514, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(23514, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(32136, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(32136, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(10519, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(10519, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(10519, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(10519, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(22975, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(22975, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(22975, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(22975, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(19065, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(19065, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(19065, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(19065, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(8190, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(8190, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(15365, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(15365, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(15365, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(15365, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(31138, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(31138, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(31138, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(31138, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(8213, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(8213, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(24591, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(24591, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(24591, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(24591, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(33621, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(33621, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(33621, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(33621, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(13598, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(13598, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(32997, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(32997, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(32997, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(32997, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(11313, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(11313, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(11313, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(11313, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(26795, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(26795, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26795, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(26795, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(15436, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(15436, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(25740, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(25740, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(25740, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(25740, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(12851, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(12851, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(12851, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(12851, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(29476, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(29476, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(29476, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(29476, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(22327, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(22327, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(22327, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(22327, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(23564, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(23564, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(23564, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(23564, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(30641, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(30641, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(30641, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(30641, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(28968, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(28968, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(28968, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(28968, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(28662, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(28662, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(10470, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(10470, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(10470, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(10470, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(6767, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(6767, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(6767, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(6767, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(26488, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(26488, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26488, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(26488, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(27499, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(27499, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(27499, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(27499, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(13941, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(13941, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(9784, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(9784, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(9784, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(9784, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(4065, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(4065, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(4065, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(4065, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(10946, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(10946, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(26852, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(26852, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26852, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(26852, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(7652, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(7652, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(7652, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(7652, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(28493, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(28493, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(28493, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(28493, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(3128, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(3128, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(3128, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(3128, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(2088, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(2088, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(2088, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(2088, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(16223, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(16223, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(16223, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(16223, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(7344, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(7344, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(7344, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(15429, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(15429, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(15429, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(15429, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(28998, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(28998, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(28998, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(28998, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(33685, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(33685, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(13357, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(13357, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(13357, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(13357, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(2878, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(2878, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(20807, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(20807, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(20807, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(20807, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(20976, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(20976, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(33806, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(33806, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(33806, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(33806, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(29358, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(29358, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(29358, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(29358, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(26727, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26727, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(14339, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(14339, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(25797, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(25797, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(25797, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(25797, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(26377, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(26377, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26377, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(26377, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(21209, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(21209, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(21209, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(21209, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(1051, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(1051, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(31397, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(31397, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(26969, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(26969, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26969, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(26969, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(19990, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(19990, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(19990, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(19990, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(5027, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(5027, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(13611, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(13611, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(26349, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(26349, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26349, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(26349, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(33447, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(33447, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(33447, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(33447, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(29993, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(29993, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(12424, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(12424, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(12424, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(12424, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(22160, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(22160, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(32162, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(32162, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(32162, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(32162, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(912, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(912, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(912, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(912, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(6155, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(6155, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(11873, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(11873, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(11873, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(11873, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(26846, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(26846, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26846, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(26846, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(27232, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(27232, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(27232, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(27232, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(13294, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(13294, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(13294, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(13294, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(20887, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(20887, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(20887, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(20887, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(966, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(966, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(26387, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(26387, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(26387, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(26387, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(1581, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(1581, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(1581, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(1581, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(29475, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(29475, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(29475, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(29475, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(15040, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(15040, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(15869, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(15869, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(15869, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(15869, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(6780, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(6780, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(6780, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(6780, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(19284, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(19284, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(19284, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(19284, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(28664, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(28664, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(7141, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(7141, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(7141, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(7141, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(32233, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(32233, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(25412, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(25412, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(25412, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(25412, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(10301, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(10301, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(9489, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(9489, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(27942, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(27942, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(1042, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(1042, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(32104, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(32104, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(32104, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(32104, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(32108, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(32108, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(7843, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(7843, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(7843, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(7843, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(19345, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(19345, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(7741, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(7741, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(7741, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(7741, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(23052, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(23052, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(15101, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(15101, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(15101, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(15101, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(13364, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(13364, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(20025, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(20025, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(28022, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(28022, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(28022, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(28022, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(4222, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(4222, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(22974, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(22974, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(15427, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(15427, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(15427, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(15427, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(16425, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(16425, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(16425, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(16425, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(16895, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(16895, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(16895, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(16895, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(3726, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(3726, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(3726, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(3726, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(17818, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(17818, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(17818, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(17818, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(8208, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(8208, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(31648, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(31648, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(29511, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(29511, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(29511, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(29511, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(21995, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(21995, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(21995, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(21995, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(15408, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(15408, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(15408, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(15408, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(8842, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(8842, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(8842, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(8842, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(19661, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(19661, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(19661, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(19661, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(10337, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(10337, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(10337, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(10337, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(29087, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(29087, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(29087, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(29087, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(5252, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcohol†allopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatin†azithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydrate†chlorpropamidecholestyramine†cimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamide†danazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(5252, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(5252, 'linezolid', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 2–9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0–∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(5252, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(4638, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(4638, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(5422, 'orlistat', 'N/A', 'minor', 'XENICAL inhibited absorption of a vitamin E acetate supplement.', 'DailyMed'),
(5422, 'selumetinib', 'N/A', 'minor', 'Vitamin E Clinical Impact •KOSELUGO capsules contain vitamin E and daily vitamin E intake that exceeds the recommended or safe limits may increase the risk of bleeding. Management •Supplemental vitamin E is not recommended if daily vitamin E intake (including the amount of vitamin E in KOSELUGO capsules and supplement) will exceed the recommended or safe limits.', 'DailyMed'),
(9298, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Oral Medications: OZEMPIC delays gastric emptying. May impact absorption of concomitantly administered oral medications (7.2). 7.1 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin The risk of hypoglycemia is increased when OZEMPIC is used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin. The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogues) or insulin [see Warnings and Precautions (5.5)]. 7.2 Oral Medications OZEMPIC causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications. In clinical pharmacology trials, semaglutide did not affect the absorpti', 'DailyMed'),
(271, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Oral Medications: OZEMPIC delays gastric emptying. May impact absorption of concomitantly administered oral medications (7.2). 7.1 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin The risk of hypoglycemia is increased when OZEMPIC is used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin. The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogues) or insulin [see Warnings and Precautions (5.5)]. 7.2 Oral Medications OZEMPIC causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications. In clinical pharmacology trials, semaglutide did not affect the absorpti', 'DailyMed'),
(84, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Oral Medications: OZEMPIC delays gastric emptying. May impact absorption of concomitantly administered oral medications (7.2). 7.1 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin The risk of hypoglycemia is increased when OZEMPIC is used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin. The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogues) or insulin [see Warnings and Precautions (5.5)]. 7.2 Oral Medications OZEMPIC causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications. In clinical pharmacology trials, semaglutide did not affect the absorpti', 'DailyMed'),
(7537, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Oral Medications: OZEMPIC delays gastric emptying. May impact absorption of concomitantly administered oral medications (7.2). 7.1 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin The risk of hypoglycemia is increased when OZEMPIC is used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin. The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogues) or insulin [see Warnings and Precautions (5.5)]. 7.2 Oral Medications OZEMPIC causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications. In clinical pharmacology trials, semaglutide did not affect the absorpti', 'DailyMed'),
(7545, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Oral Medications: OZEMPIC delays gastric emptying. May impact absorption of concomitantly administered oral medications (7.2). 7.1 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin The risk of hypoglycemia is increased when OZEMPIC is used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin. The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogues) or insulin [see Warnings and Precautions (5.5)]. 7.2 Oral Medications OZEMPIC causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications. In clinical pharmacology trials, semaglutide did not affect the absorpti', 'DailyMed'),
(13583, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Oral Medications: OZEMPIC delays gastric emptying. May impact absorption of concomitantly administered oral medications (7.2). 7.1 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin The risk of hypoglycemia is increased when OZEMPIC is used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin. The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogues) or insulin [see Warnings and Precautions (5.5)]. 7.2 Oral Medications OZEMPIC causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications. In clinical pharmacology trials, semaglutide did not affect the absorpti', 'DailyMed'),
(9812, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Oral Medications: OZEMPIC delays gastric emptying. May impact absorption of concomitantly administered oral medications (7.2). 7.1 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin The risk of hypoglycemia is increased when OZEMPIC is used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin. The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogues) or insulin [see Warnings and Precautions (5.5)]. 7.2 Oral Medications OZEMPIC causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications. In clinical pharmacology trials, semaglutide did not affect the absorpti', 'DailyMed'),
(15698, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Oral Medications: OZEMPIC delays gastric emptying. May impact absorption of concomitantly administered oral medications (7.2). 7.1 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin The risk of hypoglycemia is increased when OZEMPIC is used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin. The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogues) or insulin [see Warnings and Precautions (5.5)]. 7.2 Oral Medications OZEMPIC causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications. In clinical pharmacology trials, semaglutide did not affect the absorpti', 'DailyMed'),
(15697, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Oral Medications: OZEMPIC delays gastric emptying. May impact absorption of concomitantly administered oral medications (7.2). 7.1 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin The risk of hypoglycemia is increased when OZEMPIC is used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin. The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogues) or insulin [see Warnings and Precautions (5.5)]. 7.2 Oral Medications OZEMPIC causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications. In clinical pharmacology trials, semaglutide did not affect the absorpti', 'DailyMed'),
(6996, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Oral Medications: OZEMPIC delays gastric emptying. May impact absorption of concomitantly administered oral medications (7.2). 7.1 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin The risk of hypoglycemia is increased when OZEMPIC is used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin. The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogues) or insulin [see Warnings and Precautions (5.5)]. 7.2 Oral Medications OZEMPIC causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications. In clinical pharmacology trials, semaglutide did not affect the absorpti', 'DailyMed'),
(13327, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Oral Medications: OZEMPIC delays gastric emptying. May impact absorption of concomitantly administered oral medications (7.2). 7.1 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin The risk of hypoglycemia is increased when OZEMPIC is used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin. The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogues) or insulin [see Warnings and Precautions (5.5)]. 7.2 Oral Medications OZEMPIC causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications. In clinical pharmacology trials, semaglutide did not affect the absorpti', 'DailyMed'),
(25675, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(25675, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(25675, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(25675, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(25675, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(25675, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25675, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25675, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25675, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(25675, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25675, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25675, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(25675, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(25668, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(25668, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(25668, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(25668, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(25668, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(25668, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25668, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25668, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25668, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(25668, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25668, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25668, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(25668, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(14768, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(14768, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(14768, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(14768, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(14768, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(14768, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(14768, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(14768, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(14768, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(14768, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(14768, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(14768, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(14768, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(25667, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(25667, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(25667, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(25667, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(25667, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(25667, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25667, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25667, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25667, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(25667, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25667, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25667, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(25667, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(25756, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(25756, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(25756, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(25756, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(25756, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(25756, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25756, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25756, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(25756, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(25756, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25756, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25756, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(25756, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(25665, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(25665, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(25665, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(25665, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(25665, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(25665, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25665, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25665, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25665, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(25665, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25665, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25665, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(25665, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(13074, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(13074, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(13074, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(13074, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(13074, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(13074, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(13074, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(13074, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(13074, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(13074, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(13074, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(13074, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(13074, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(11709, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(11709, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(11709, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(11709, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(11709, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(11709, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(11709, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(11709, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(11709, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(11709, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(11709, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(11709, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(11709, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(14767, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(14767, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(14767, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(14767, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(14767, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(14767, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(14767, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(14767, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(14767, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(14767, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(14767, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(14767, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(14767, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(26089, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(26089, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(26089, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(26089, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(26089, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(26089, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(26089, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(26089, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(26089, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(26089, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(26089, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(26089, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(26089, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(13078, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(13078, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(13078, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(13078, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(13078, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(13078, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(13078, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(13078, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(13078, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(13078, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(13078, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(13078, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(13078, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(28536, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(28536, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(28536, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(28536, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(28536, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(28536, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(28536, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(28536, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(28536, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(28536, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(28536, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(28536, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(28536, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(25661, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(25661, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(25661, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(25661, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(25661, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(25661, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25661, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25661, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25661, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(25661, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25661, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25661, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(25661, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(25634, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(25634, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(25634, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(25634, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(25634, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(25634, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25634, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25634, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25634, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(25634, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25634, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25634, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(25634, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(31840, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(31840, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(31840, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(31840, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(31840, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(31840, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(31840, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(31840, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(31840, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(31840, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(31840, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(31840, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(31840, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(15189, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(15189, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(15189, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(15189, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(15189, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(15189, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(15189, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(15189, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(15189, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(15189, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(15189, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(15189, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(15189, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(13092, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(13092, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(13092, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(13092, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(13092, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(13092, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(13092, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(13092, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(13092, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(13092, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(13092, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(13092, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(13092, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(25660, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(25660, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(25660, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(25660, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(25660, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(25660, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25660, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25660, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25660, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(25660, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25660, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25660, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(25660, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(13082, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(13082, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(13082, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(13082, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(13082, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(13082, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(13082, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(13082, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(13082, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(13082, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(13082, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(13082, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(13082, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(13093, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(13093, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(13093, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(13093, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(13093, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(13093, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(13093, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(13093, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(13093, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(13093, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(13093, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(13093, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(13093, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(13095, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(13095, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(13095, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(13095, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(13095, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(13095, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(13095, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(13095, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(13095, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(13095, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(13095, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(13095, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(13095, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(25635, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(25635, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(25635, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(25635, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(25635, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(25635, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25635, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25635, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25635, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(25635, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25635, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25635, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(25635, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(11701, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(11701, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(11701, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(11701, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(11701, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(11701, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(11701, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(11701, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(11701, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(11701, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(11701, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(11701, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(11701, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(9845, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(9845, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(9845, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(9845, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(9845, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(9845, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(9845, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(9845, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(9845, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(9845, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(9845, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(9845, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(9845, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(25658, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(25658, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(25658, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(25658, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(25658, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(25658, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25658, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25658, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25658, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(25658, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25658, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25658, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(25658, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(13075, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(13075, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(13075, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(13075, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(13075, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(13075, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(13075, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(13075, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(13075, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(13075, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(13075, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(13075, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(13075, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(13096, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(13096, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(13096, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(13096, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(13096, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(13096, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(13096, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(13096, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(13096, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(13096, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(13096, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(13096, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(13096, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(18911, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(18911, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(18911, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(18911, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(18911, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(18911, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(18911, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(18911, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(18911, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(18911, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(18911, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(18911, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(18911, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(28457, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(28457, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(28457, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(28457, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(28457, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(28457, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(28457, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(28457, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(28457, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(28457, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(28457, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(28457, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(28457, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(11707, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(11707, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(11707, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(11707, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(11707, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(11707, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(11707, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(11707, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(11707, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(11707, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(11707, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(11707, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(11707, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(25663, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(25663, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(25663, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(25663, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(25663, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(25663, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25663, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25663, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25663, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(25663, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25663, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25663, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(25663, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(25678, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(25678, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(25678, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(25678, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(25678, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(25678, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25678, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25678, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25678, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(25678, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25678, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25678, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(25678, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(11705, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(11705, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(11705, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(11705, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(11705, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(11705, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(11705, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(11705, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(11705, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(11705, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(11705, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(11705, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(11705, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(16817, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(16817, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(16817, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(16817, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(16817, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(16817, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(16817, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(16817, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(16817, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(16817, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(16817, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(16817, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(16817, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(25755, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(25755, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(25755, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(25755, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(25755, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(25755, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25755, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25755, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25755, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(25755, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25755, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25755, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(25755, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(25672, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(25672, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(25672, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(25672, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(25672, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(25672, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25672, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25672, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25672, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(25672, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25672, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25672, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(25672, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(3065, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(3065, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(3065, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(3065, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(3065, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(3065, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(3065, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(3065, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(3065, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(3065, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(3065, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(3065, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(3065, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(16816, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(16816, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(16816, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(16816, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(16816, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(16816, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(16816, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(16816, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(16816, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(16816, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(16816, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(16816, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(16816, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(25757, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(25757, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(25757, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(25757, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(25757, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(25757, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25757, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25757, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25757, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(25757, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25757, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25757, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(25757, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(11698, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(11698, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(11698, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(11698, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(11698, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(11698, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(11698, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(11698, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(11698, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(11698, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(11698, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(11698, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(11698, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(18912, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(18912, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(18912, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(18912, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(18912, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(18912, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(18912, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(18912, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(18912, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(18912, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(18912, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(18912, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(18912, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(25673, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(25673, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(25673, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(25673, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(25673, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(25673, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25673, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25673, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25673, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(25673, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25673, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25673, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(25673, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(11700, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(11700, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(11700, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(11700, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(11700, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(11700, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(11700, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(11700, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(11700, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(11700, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(11700, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(11700, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(11700, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(25633, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(25633, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(25633, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(25633, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(25633, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(25633, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25633, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25633, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25633, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(25633, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25633, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25633, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(25633, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(25674, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(25674, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(25674, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(25674, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(25674, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(25674, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25674, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25674, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25674, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(25674, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25674, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25674, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(25674, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(25659, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(25659, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(25659, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(25659, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(25659, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(25659, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25659, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25659, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25659, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(25659, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25659, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25659, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(25659, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(25758, 'ramipril', 'N/A', 'minor', 'Drug Interactions With nonsteroidal anti-inflammatory agents: Rarely, concomitant treatment with ACE inhibitors and nonsteroidal anti-inflammatory agents have been associated with worsening of renal failure and an increase in serum potassium.With diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. (See DOSAGE AND ADMINISTRATION.)With potassium supplements and potassium-sparing diuretics: Ramipril can attenuate potassium loss caused by thiazide diuret', 'DailyMed'),
(25758, 'iron', 'N/A', 'minor', 'Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.', 'DailyMed'),
(25758, 'aliskiren hemifumarate and hydrochlorothiazide', 'N/A', 'major', 'Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.', 'DailyMed'),
(25758, 'telmisartan', 'N/A', 'major', 'In a large-scale, long-term clinical efficacy study, the combination of telmisartan and ramipril resulted in an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, dialysis) compared with groups receiving either drug alone. Therefore, concomitant use of telmisartan and ramipril is not recommended [see 5.7 Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)].', 'DailyMed'),
(25758, 'telmisartan and hydrochlorothiazide', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3 and 2.1 fold, respectively, and Cmax and AUC of ramiprilat 2.4 and 1.5 fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.', 'DailyMed'),
(25758, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25758, 'temsirolimus', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25758, 'temsirolimus injection', 'N/A', 'moderate', '7.3 Angioedema with ACE inhibitors and Calcium Channel Blokers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine. Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with an angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).', 'DailyMed'),
(25758, 'telmisartan and amlodipine', 'N/A', 'minor', 'Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3- and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4- and 1.5-fold, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Co-administration of telmisartan and ramipril is not recommended.', 'DailyMed'),
(25758, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25758, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention.', 'DailyMed'),
(25758, 'patiromer', 'N/A', 'major', 'Table 3: No observed clinically important drug interactions of Veltassa Angiotensin-converting enzyme (ACE) inhibitors Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril Angiotensin II receptor blockers (ARB) Azilsartan, candesartan, irbesartan, losartan, olmesartan, valsartan β-adrenoceptor blockers (β-blocker) Metoprolol Loop diuretics Furosemide, bumetanide, torasemide Mineralocorticoid receptor antagonists (MRA) Eplerenone, finerenone, spironolactone Neprilysin inhibitors Sacubitril Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Canagliflozin, dapagliflozin, empagliflozin Antibiotics Trimethoprim, amoxicillin, cephalexin Anticoagulants Warfarin, apixaban, rivaroxaban Anti-parathyroid agents and Thyroid preparations Cinacalcet An', 'DailyMed'),
(25758, 'drug_class', 'N/A', 'moderate', '7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased.', 'DailyMed'),
(10319, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(19413, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(18215, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(8009, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(24944, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(14187, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(33793, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(18019, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(25447, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(24526, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(26323, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(16970, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(6547, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(26889, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(26767, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(10760, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(21224, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(29551, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(22307, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(1820, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(5220, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(24648, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(27062, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(896, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(33342, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(29004, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(6596, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(213, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(13482, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(23929, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(21996, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(4523, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(520, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(32582, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(20215, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(7427, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(11335, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(12801, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(7426, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(18255, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(17373, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(21111, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(28705, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(29113, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(28539, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(30633, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(17902, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(16471, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(33377, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(30545, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(17411, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(33113, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(26211, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(22964, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(5194, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(13179, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(22359, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(8196, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(26578, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(2269, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(5550, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(6243, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(2735, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(17331, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(20041, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(7145, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(26737, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(20262, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(24658, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(9601, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(22540, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(27294, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(21341, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(29949, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(24524, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(22937, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(13617, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(8350, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(32514, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(26953, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(3855, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(28229, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(26627, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(21627, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(33599, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(32373, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(15609, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(25208, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(12420, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(1722, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(16472, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(5989, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(26448, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(12860, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(26819, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(22308, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(3759, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(5200, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(15608, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(9740, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(19579, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(21640, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(21371, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(14440, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(30344, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(27715, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(13654, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(3627, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(25279, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(21170, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(1765, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(3655, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(26449, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(4956, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(23828, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(32196, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(30729, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(13299, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(20570, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(32332, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(13655, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(3447, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(19495, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(27502, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(13415, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(21556, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(3696, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(32126, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(13613, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(31067, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(29741, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(32852, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(12049, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(27469, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(24527, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(21433, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(33606, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(17119, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(3460, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(15468, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(6593, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(27503, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(31720, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(462, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(23257, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(30077, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(23300, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(26511, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(30335, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(362, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(1113, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(28043, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(17712, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(24649, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(4625, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(33284, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(4848, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(10320, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(32208, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(26973, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(26792, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(9602, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(24659, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(22111, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(32436, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(6158, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(7894, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(25066, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(27290, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(14185, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(15875, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(28596, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(1391, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(33495, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(1559, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(10054, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(24529, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(32202, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(16195, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(20814, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(3327, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(26522, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(13620, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(3489, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(2954, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(9084, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(19285, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(33865, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(298, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(4089, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(28912, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(30860, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(32330, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(12053, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(17581, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(13807, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(20610, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(639, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(25825, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(8022, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(3392, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(17306, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(13295, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(22162, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(25798, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(7899, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(24518, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(20603, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(32698, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(31838, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(26738, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(32138, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(2962, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(23682, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(17856, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(19991, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(23350, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(14383, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(9588, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(5143, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(21345, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(23351, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(27233, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(12382, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(26888, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(27990, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(14651, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(26732, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(31020, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(13377, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(12312, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(32463, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(26397, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(26434, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(32077, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(24623, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(6827, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(2446, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(7690, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(30753, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(21577, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(17671, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(14295, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(1770, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(12661, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(25200, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(29462, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(32078, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(18252, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(26521, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(4303, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(16748, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(20211, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(16894, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(15922, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(33052, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(16017, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(23205, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(17904, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(23217, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(15925, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(7617, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(26908, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(14605, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(13206, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(28421, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(21420, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(30909, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(31306, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(4846, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(32109, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(15324, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(31837, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(13869, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(6813, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(22911, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(6981, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(21393, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(3300, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(29086, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(13414, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(23612, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(4622, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(32340, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(20191, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(25411, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(28669, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(32063, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(15946, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(29613, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(25535, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(24622, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(31715, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(29755, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(26818, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(6121, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(29639, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(20471, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(31068, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(2719, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(2146, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(24519, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(1181, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(6594, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(30331, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(25761, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(13815, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(30343, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(26739, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(3591, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(31828, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(31848, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(2813, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(7465, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(25203, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(16690, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(31362, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(21970, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(18119, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(19042, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(26670, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(33626, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(28661, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(31797, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(6156, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(27771, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(30127, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(21191, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(9541, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(32201, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(21950, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(605, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(28213, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(32062, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(24662, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(26896, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(27977, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(7907, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(3736, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(19640, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(24525, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(11654, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(4129, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(33664, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(30752, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(17311, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(20608, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(2608, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(19482, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(26743, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(13665, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(8242, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(2119, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(10876, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(25952, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(28276, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(8815, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(1725, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(14199, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(28635, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(32963, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(22899, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(27910, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(26734, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(14947, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(33175, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(7046, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(25499, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(19735, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(2061, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(15282, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(14382, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(32125, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(16029, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(18858, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(32584, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(18399, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(15395, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(26471, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(32313, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(19372, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(4286, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(15507, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(8533, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(19371, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(1364, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(13734, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(24515, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(30803, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(29163, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(30130, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(21933, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(7686, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(15712, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(9012, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(3418, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(17057, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(31999, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(33859, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(32490, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(31472, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(29308, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(32962, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(27229, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(8024, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(5228, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(16920, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(307, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(6432, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(26899, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(11519, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(26780, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(3962, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(18256, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(18153, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(2958, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(3193, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(13579, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(10353, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(25278, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(1515, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(13618, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(3321, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(10769, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(32524, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(28973, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(25410, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(11152, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(2158, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(16892, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(23289, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(1952, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(21453, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(11557, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(32905, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(27464, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(17433, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(8015, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(22176, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(20205, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(3055, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(4655, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(30152, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(24517, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(22293, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(17680, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(6328, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(24272, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed'),
(24521, 'pyridostigmine bromide', 'N/A', 'minor', '(7.4)Drugs converted to pantothenic acid (e.g., dexpanthenol): Additive effect. 7.5 Drugs Converted to Pantothenic Acid (e.g., Dexpanthenol) Theoretically, drugs such as dexpanthenol, which are converted to pantothenic acid in vivo, may have additive effects with pyridostigmine by increasing production of acetylcholine.', 'DailyMed');

